secwatch.observer — SEC 8-K summary
======================================

Issuer:     Keros Therapeutics, Inc. (KROS)
CIK:        0001664710
Form:       8-K
Filed at:   2026-03-04T23:59:59+00:00
Accession:  0001664710-26-000017
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Keros Therapeutics reports Q4 net loss $23.5M, full-year net income $87.0M
--------------------------------------------------------------------------

- Q4 2025 net loss $23.5M vs. $46.0M loss in Q4 2024; FY 2025 net income $87.0M vs. $187.4M loss in FY 2024.
- Cash and equivalents $287.4M as of Dec 31, 2025, expected to fund operations into first half of 2028.
- R&D expenses fell to $17.9M (Q4) and $129.6M (FY) due to transition of elritercept costs to Takeda.
- Charles Newton appointed to board effective March 9, 2026; Carl Gordon steps down. Esther Cho promoted to Chief Legal Officer.
- Phase 2 trial of rinvatercept for DMD expected to start in Q2 2026; ALS regulator engagement planned for H2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1664710/000166471026000017/0001664710-26-000017-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1664710/000166471026000017/kros-20260304.htm
  HTML page:      https://secwatch.observer/filing/0001664710-26-000017

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer